Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)

Authors :: Eberhardt, Wilfried
Gauler, Thomas
Pöttgen, Christoph
Friedel, G.
Veit, S.
Heinrich, V.
Welter, Stefan
Spengler, W.
Kimmich, M.
Fischer, B.
Schmidberger, H.
Gkika, E.
Cordes, S.
Hepp, R.
Luetke-Brintrup, D.
Lehmann, Nils
Schuler, Martin
Jöckel, Karl-Heinz
Stamatis, Georgios
Stuschke, Martin
ESPATUE AIO ARO Clinical Trials
Source :: Journal of Clinical Oncology. 32:7510-7510
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 7510 Background: Def ccCRTx or ccCRTx + S are accepted therapies (Tx) for OP+ stage IIIA(N2) NSCLC (Albain 2009). Our multicenter phase-II showed efficacy of CTx + ccCRTx + S in IIIA(N2) / sel IIIB...

Subjects :: Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
Medizin
non-small cell lung cancer (NSCLC)
medicine.disease
Concurrent chemoradiotherapy
Surgery
Oncology
medicine
In patient
Stage IIIa
business

Full Text Access

Tools